Search results for "coagulants"

showing 10 items of 248 documents

Lemierre Syndrome: Clinical Update and Protocol for a Systematic Review and Individual Patient Data Meta-analysis.

2018

Lemierre syndrome usually affects otherwise healthy adolescents or young adults and occurs at an overall rate of 1 to 10 cases per million person-years with an estimated fatality rate of 4 to 9%. Diagnostic criteria remain debated and include acute neck/head bacterial infection (often tonsillitis caused by anaerobes at high potential for sepsis and vascular invasion, notably Fusobacterium necrophorum) complicated by local vein thrombosis, usually involving the internal jugular vein, and systemic septic embolism. Medical treatment is based on antibiotic therapy with anaerobic coverage, anticoagulant drugs and supportive care in case of sepsis. Surgical procedures can be required, including d…

AdultMalemedicine.medical_specialtyTonsillitisved/biology.organism_classification_rank.species030204 cardiovascular system & hematologySepsis03 medical and health sciencesYoung Adult0302 clinical medicineFusobacterium necrophorumJugular veinCase fatality ratemedicineHumansIntensive care medicine610 Medicine & healthInternal jugular veinSeptic embolismVenous Thrombosisbusiness.industryved/biologyAnticoagulantsHematologyLemierre Syndromemedicine.diseaseLemierre Study GroupPrognosisAnti-Bacterial AgentsVenous thrombosisFusobacterium necrophorumbusiness030215 immunologyHamostaseologie
researchProduct

Distinct patterns of heparin affinity chromatography VLDL1 and VLDL2 subfractions in the different dyslipidaemias

2007

Very low density lipoprotein (VLDL) 1 and 2 were fractionated by heparin affinity chromatography into a bound and an unbound fraction and the different subfractions were quantified in 17 normolipidaemic (NL), 13 hypercholesterolaemic (HC), 10 hypertriglyceridaemic (HTG) and 11 combined hyperlipidaemic subjects (CHL). Unbound VLDL1 and VLDL2 were, respectively, 1.9- and 2.2-fold richer in triglycerides than bound VLDL1 and VLDL2. In HTG and CHL the concentration of all the VLDL subfractions was increased and plasma triglyceride level was correlated to unbound VLDL1 and to bound VLDL1 (respectively, r=0.86 (p<0.001) and r=0.77 (p<0.01) in HTG and r=0.73 (p<0.001) and r=0.62 (p<0.05) in CHL). …

AdultMalemedicine.medical_specialtyVery low-density lipoproteinHypercholesterolemiaHyperlipidemia Familial CombinedLipoproteins VLDLChromatography AffinityGlycosaminoglycanchemistry.chemical_compoundAffinity chromatographyInternal medicinemedicineHumansApolipoproteins BDyslipidemiasHypertriglyceridemiaTriglycerideHeparinCholesterolHypertriglyceridemiaAnticoagulantsHeparinMiddle Agedmedicine.diseaseEndocrinologychemistryFemaleCardiology and Cardiovascular MedicineUltracentrifugationProtein BindingLipoproteinmedicine.drugAtherosclerosis
researchProduct

Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study.

2011

Abstract The safest duration of anticoagulation after idiopathic deep vein thrombosis (DVT) is unknown. We conducted a prospective study to assess the optimal duration of vitamin K antagonist (VKA) therapy considering the risk of recurrence of thrombosis according to residual vein thrombosis (RVT). Patients with a first unprovoked DVT were evaluated for the presence of RVT after 3 months of VKA administration; those without RVT suspended VKA, while those with RVT continued oral anticoagulation for up to 2 years. Recurrent thrombosis and/or bleeding events were recorded during treatment (RVT group) and 1 year after VKA withdrawal (both groups). Among 409 patients evaluated for unprovoked DVT…

AdultMalemedicine.medical_specialtyVitamin Kmedicine.drug_classDeep veinHemorrhageDrug Administration ScheduleSettore MED/15 - Malattie Del SangueRecurrenceRisk Factorsdeep vein thrombosis (DVT)Residual vein thrombosismedicineHumansProspective Studiesdeep vein thrombosis (DVT); vitamin K antagonist (VKA) therapy; Residual vein thrombosisProspective cohort studyAgedUltrasonographyVenous Thrombosisbusiness.industryAcenocoumarolAnticoagulantsHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedmedicine.diseaseThrombosisConfidence intervalSurgeryClinical trialVein thrombosisvitamin K antagonist (VKA) therapymedicine.anatomical_structureLower ExtremityRelative riskFemaleWarfarinbusiness
researchProduct

Is it necessary to alter anticoagulation therapy for tooth extraction in patients taking direct oral anticoagulants?

2017

Background The number of patients using direct oral anticoagulants (DOACs) instead of vitamin K antagonists (VKA) is increasing and there is limited data on the safety of tooth extractions in patients taking DOACs. The aim of this study was to compare the amount of bleeding (AOB) and postoperative complications after tooth extractions between patients taking VKAs and patients taking DOACs without altering the anticoaguation therapy. Material and Methods The study consisted of four groups: Direct thrombin inhibitor group, factor Xa inhibitor group, warfarin group and a control group. A single tooth was extracted in each patient and routine coagulation test values were recorded prior to extra…

AdultMalemedicine.medical_specialtyVitamin Kmedicine.drug_mechanism_of_actionFactor Xa InhibitorAdministration OralPostoperative Hemorrhage030204 cardiovascular system & hematologyDirect oral anticoagulants03 medical and health sciencesPostoperative Complications0302 clinical medicineRivaroxabanChi-square testmedicineHumansApixabanProspective StudiesProspective cohort studyGeneral DentistryAgedAged 80 and overbusiness.industryResearchWarfarinAnticoagulants030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]DabigatranSurgeryRegimenOtorhinolaryngologyCoagulationDirect thrombin inhibitorUNESCO::CIENCIAS MÉDICASTooth ExtractionFemaleSurgeryAnalysis of varianceOral Surgerybusinessmedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer.

2018

After acute proximal deep vein thrombosis (DVT) the thrombotic mass decreases, especially during the first months of anticoagulation. The persistence of residual vein obstruction (RVO) may predict future recurrence in patients with cancer-associated DVT. We aimed to evaluate the proportion of patients with RVO after an episode of cancer associated isolated distal DVT (IDDVT), to identify variables associated with RVO, and to provide initial evidence of its association with recurrent VTE. We performed a post-hoc analysis of a multicenter cohort study of patients with isolated cancer-associated acute IDDVT. We included patients who underwent a control ultrasonography at the end of the anticoa…

AdultMalemedicine.medical_specialtymedicine.drug_classDeep vein030204 cardiovascular system & hematologyCompression ultrasound; Distal deep vein thrombosis; Recurrence; Residual vein obstruction; Venous thromboembolism; Hematology; Cardiology and Cardiovascular Medicine03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsInternal medicineNeoplasmsmedicineHumansIn patientDistal deep vein thrombosiAgedUltrasonographyVenous ThrombosisHematologybusiness.industryRisk FactorAnticoagulantAnticoagulantCancerAnticoagulantsHematologyVenous ThromboembolismCompression ultrasoundMiddle Agedmedicine.diseaseThrombosisSurgeryDiscontinuationmedicine.anatomical_structureDistal deep vein thrombosis030220 oncology & carcinogenesisResidual vein obstructionAcute DiseaseNeoplasmFemalebusinessCardiology and Cardiovascular MedicineHumanCohort studyJournal of thrombosis and thrombolysis
researchProduct

Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation base…

2008

Abstract Residual vein thrombosis (RVT) indicates a prothrombotic state and is useful for evaluating the optimal duration of oral anticoagulant treatment (OAT). Patients with a first episode of deep vein thrombosis, treated with OAT for 3 months, were managed according to RVT findings. Those with RVT were randomized to either stop or continue anticoagulants for 9 additional months, whereas in those without RVT, OAT was stopped. Outcomes were recurrent venous thromboembolism and/or major bleeding. Residual thrombosis was detected in 180 (69.8%) of 258 patients; recurrent events occurred in 27.2% of those who discontinued (25/92; 15.2% person-years) and 19.3% of those who continued OAT (17/88…

AdultMalemedicine.medical_specialtymedicine.drug_classDeep veinImmunologyHemorrhageBiochemistryDrug Administration ScheduleSettore MED/15 - Malattie Del SangueDeep vein thrombosioral anticoagulantSecondary PreventionmedicineHumansAgedUltrasonographyVenous ThrombosisFirst episoderesidual vein thrombosisVascular diseasebusiness.industryAnticoagulantHazard ratioAnticoagulantsCell BiologyHematologyMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareThrombosisConfidence intervalSurgeryVenous thrombosisTreatment Outcomemedicine.anatomical_structureFemalebusinessBlood
researchProduct

Monitoring prothrombin fragment 1+2 during initiation of oral anticoagulant therapy after intracoronary stenting

1992

Patients with intracoronary stent implantation are treated with aggressive anticoagulant and antiplatelet therapy consisting of high-dose heparin, phenprocoumon, acetylsalicylic acid, dipyridamole, and the infusion of dextran to prevent a subacute thrombotic occlusion of the stented segment. In an effort to optimize this treatment by reducing both imminent bleeding complications and subacute thrombotic occlusion, the concentrations of prothrombin fragment 1 + 2 (F 1 + 2) were determined after intracoronary Palmaz-Schatz stent implantation in 19 consecutive patients. The F 1 + 2 concentrations after stent implantation and before the initiation of oral anticoagulant therapy (OAT) were 0.35 nm…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentUrologyAdministration OralPhenprocoumonmedicineHumansAngioplasty Balloon CoronaryAgedChemotherapyHeparinbusiness.industryPROTHROMBIN FRAGMENT 1.2AnticoagulantAnticoagulantsHematologyGeneral MedicineHeparinMiddle AgedThrombophlebitismedicine.diseaseThrombosisPeptide FragmentsDipyridamoleHeart Valve ProsthesisAnesthesiaPhenprocoumonFemaleProthrombinStentsPulmonary EmbolismComplicationbusinessmedicine.drugAnnals of Hematology
researchProduct

How to Handle Arterial Conduits in Liver Transplantation? Evidence From the First Multicenter Risk Analysis

2020

OBJECTIVE: The aims of the present study were to identify independent risk factors for conduit occlusion, compare outcomes of different AC placement sites, and investigate whether postoperative platelet antiaggregation is protective. BACKGROUND: Arterial conduits (AC) in liver transplantation (LT) offer an effective rescue option when regular arterial graft revascularization is not feasible. However, the role of the conduit placement site and postoperative antiaggregation is insufficiently answered in the literature. STUDY DESIGN: This is an international, multicenter cohort study of adult deceased donor LT requiring AC. The study included 14 LT centers and covered the period from January 2…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentLiver transplantationRevascularizationRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsLTOcclusionmedicineClinical endpointHumansAorta AbdominalVascular Patencybusiness.industryAnastomosis SurgicalGraft SurvivalAnticoagulantsThrombosisPerioperativeMiddle AgedArterial occlusionSurgeryLiver TransplantationRegimenLiver030220 oncology & carcinogenesis030211 gastroenterology & hepatologySurgeryFemalebusinessVascular Surgical ProceduresCohort study
researchProduct

Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-) acute liver failure

2003

Abstract Background/Aims Except for bleeding complications, other serious adverse reactions of coumarin anticoagulants such as hepatotoxicity or skin necrosis are comparatively rare. Nonetheless, a small number of coumarin-induced (sub-) acute liver failures has been published. Methods A retrospective analysis was performed of patients treated for liver disease between 1992 and 2002 at our department to evaluate the incidence, clinical findings and histopathology of coumarin-induced hepatotoxicity. Results The retrospective analysis revealed eight cases of phenprocoumon-induced hepatotoxicity, including three cases of (sub-) acute liver failure which resulted in two orthotopic liver transpl…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentLiver transplantationSeverity of Illness IndexGastroenterologyPhenprocoumonLiver diseaseGermanyInternal medicinemedicineHumansAdverse effectRetrospective StudiesHepatitisLiver injuryHepatologybusiness.industryLiver cellAnticoagulantsLiver Failure AcuteMiddle Agedmedicine.diseaseSurgeryAcute DiseasePhenprocoumonFemaleChemical and Drug Induced Liver InjuryComplicationbusinessmedicine.drugJournal of Hepatology
researchProduct

Primary thromboprophylaxis for adult patients on home parenteral nutrition: A comment on the 2016 ESPEN guideline

2016

AdultVenous ThrombosisParenteral Nutritionmedicine.medical_specialtyNutrition and DieteticsAdult patientsbusiness.industryAnticoagulantsVenous ThromboembolismGuideline030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicinemedicine.diseaseThrombosis03 medical and health sciencesVenous thrombosis0302 clinical medicineParenteral nutritionmedicineHumans030211 gastroenterology & hepatologyParenteral Nutrition HomeIntensive care medicinebusinessVenous thromboembolism
researchProduct